Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Catherine Mease
Institution:
United States Food and Drug Administration
Observed institution:
United States Food and Drug Administration
ORCID:
0009-0005-0156-198X
Observed ORCID:
0009-0005-0156-198X
OpenAlex ID:
A5093057375
Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
2024
·
Catherine Mease
, Kathleen L. Miller
, et al.
·
Orphanet Journal of Rare Diseases
·
13
PDF
Determining Commonalities in the Experiences of Patients with Rare Diseases: A Qualitative Analysis of US Food and Drug Administration Patient Engagement Sessions
2023
·
Catherine Mease
, Lewis J. Fermaglich
, et al.
·
Patient
·
12
PDF
The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022
2024
·
Abraham Viju Ipe
, Lewis J. Fermaglich
, et al.
·
Expert Opinion on Orphan Drugs
·
4
Trends in drug development for amyotrophic lateral sclerosis
2023
·
Selma Kraft
, Catherine Mease
, et al.
·
Nature Reviews Drug Discovery
·
4
Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
2024
·
Catherine Mease
, Kathleen L. Miller
, et al.
·
Orphanet Journal of Rare Diseases
PDF
Show more works
View as search
Works count:
5
Citation count:
33
H-index:
4
I10-index:
2
Year
Topic
Type